If you enjoy this content, please share it with a colleague
RELATED CONTENT
Like with many other aspects of healthcare, technology has been the driving force behind the evolution of radiation therapy. New advancements have given rise to new, more precise techniques for delivering maximum radiation dose to tumor volumes with minimum effect to surrounding tissue.
The American Society for Radiation Oncology (ASTRO) recently welcomed Judy Keen, Ph.D., as its director of scientific affairs, a position created to grow research participation and collaboration in the field of radiation oncology.
The American Society for Radiation Oncology (ASTRO) applauded President Obama and Vice President Biden for the “moonshot” effort in cancer research announced in the President’s State of the Union speech on Tuesday.
A new template published by the American Society for Radiation Oncology (ASTRO) standardizes and streamlines the creation of patient-focused plans for long-term cancer survivor care following radiation therapy (RT).
A new template published by the American Society for Radiation Oncology (ASTRO) standardizes and streamlines the creation of patient-focused plans for long-term cancer survivor care following radiation therapy (RT).
New data from clinical trials conducted at Penn Medicine’s Robert Proton Therapy Center demonstrate the technology's potential advantages over conventional radiation, including less side effects and survival in some cases, for several harder-to-treat tumors. This includes pancreatic, late-stage non-small cell lung and chordoma and chondrosarcoma, two rare cancers found in bone or soft tissue.
Patients with intermediate meningiomas treated with radiation therapy (RT) after surgery experienced a 96 percent three-year progression-free survival rate and had minimal adverse events, according to new research. Study findings were presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.
For patients with locally advanced esophageal cancer that has spread to the lymph nodes, radiation therapy (RT) targeting only the involved lymph nodes regions results in less toxicity without causing a statistically significant difference in loco-regional lymph nodal recurrence, distant failure and overall survival rates, according to new research. Study findings were presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.
Outcomes for pediatric patients as young as 12 months with ependymoma who are treated with immediate post-operative radiation therapy are favorable and consistent based upon the patients’ tumor surgical resection and tumor grade, according to new research. Findings from the study were presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.
The steroid dexamethasone reduces radiation-induced pain flare in cancer patients with painful bone metastases, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 57th annual meeting.